Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.68 |
| ▸ | ACE | P12821 | 3/20 | 0.65 |
| ▸ | ECE1 | P42892 | 6/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MPO | P05164 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oglufanide SCHEMBL3053743 | 1.00 | ERAP2 (0.68) | ERAP2ACEECE1KDM4EMEN1 | |
| Oglufanide SCHEMBL5822555 | 1.00 | ERAP2 (0.68) | ERAP2ACEECE1KDM4EMEN1 | |
| Oglufanide SCHEMBL5735529 | 1.00 | ERAP2 (0.68) | ERAP2ACEECE1KDM4EMEN1 | |
| Oglufanide SCHEMBL1898076 | 1.00 | ERAP2 (0.68) | ERAP2ACEECE1KDM4EMEN1 | |
| Oglufanide SCHEMBL5822559 | 1.00 | ERAP2 (0.68) | ERAP2ACEECE1KDM4EMEN1 | |
| Oglufanide SCHEMBL2042188 | 1.00 | ERAP2 (0.68) | ERAP2ACEECE1KDM4EMEN1 | |
| Oglufanide SCHEMBL24454642 | 1.00 | ERAP2 (0.68) | ERAP2ACEECE1KDM4EMEN1 | |
| Oglufanide SCHEMBL27879986 | 0.99 | ERAP2 (0.67) | ERAP2ACEECE1KDM4EMEN1 | |
| SCHEMBL31483276 | 0.98 | ERAP2 (0.69) | ERAP2ACEECE1KDM4EMEN1 | |
| SCHEMBL29603192 | 0.95 | ERAP2 (0.66) | ERAP2ACEECE1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 589 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4566670-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4511379-A2 | THERANOSTIC SILICON-FLUORIDE HETEROAROMATIC SYSTEMS AND METHODS THEREOF | Fuzionaire Theranostics, Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| CN-119301134-A | Silicon fluoride heteroaromatic systems for theranostics and methods therefor | 富齐奥奈尔治疗诊断股份有限公司 | 2025-01-10 | — | — | CN | claimed |
| EP-4403221-A2 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2024-07-24 | — | — | EP | claimed |
| US-11833246-B1 | Rectal gel with date palm phenolics and vanillic acid | King Faisal University (SA) | 2023-12-05 | — | — | US | claimed |
| US-20230355813-A1 | Theranostic Silicon-Fluoride Heteroaromatic Systems and Methods Thereof | FUZIONAIRE DIAGNOSTICS, INC. (US) | 2023-11-09 | — | — | US | claimed |
| US-11806430-B1 | Rectal gel with date palm phenolics and vanillic acid | King Faisal University (SA) | 2023-11-07 | — | — | US | claimed |
| WO-2023205755-A2 | THERANOSTIC SILICON-FLUORIDE HETEROAROMATIC SYSTEMS AND METHODS THEREOF | FUZIONAIRE DIAGNOSTICS, INC. (US) | 2023-10-26 | — | — | WO | claimed |
| CN-116789734-A | Oligopeptide group extracted from crayfish shells, extraction method and application thereof | 奇明达(北京)植物药物技术开发有限公司 | 2023-09-22 | — | — | CN | claimed |
| EP-2604264-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING VIRAL DISEASES | OBSHESTVO S OGRANICHENNOJ OTVETSTVENNOSTJU CYTONIR (RU) | 2014-09-24 | — | — | EP | claimed |
| EP-2767286-A1 | ORAL PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY GASTROINTESTINAL DISEASES | Obshestvo S Ogranichennoj Otvetstvennostju "citoNIR" (RU) | 2014-08-20 | — | — | EP | claimed |
| EP-2604264-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING VIRAL DISEASES | Obshestvo S Ogranichennoj Otvetstvennostju "citoNIR" (RU) | 2013-06-19 | — | — | EP | claimed |
| WO-2012068412-A2 | METHOD AND COMPOSITIONS FOR TREATMENT OF STAT3-RESPONSIVE CANCERS AND/OR RENAL CANCER | SCICLONE PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | WO | claimed |
| EP-1814566-B1 | TREATMENT OR PREVENTION OF HEMORRHAGIC VIRAL INFECTIONS WITH IMMUNOMODULATOR COMPOUNDS | SCICLONE PHARMACEUTICALS INC (US) | 2010-07-28 | — | — | EP | claimed |
| US-20030087830-A1 | Low molecular weight components of cartilage, complexes of metals with amino acids, DI-peptides and analogs thereof; processes for preparation and therapeutic uses thereof | AETERNA ZENTARIS INC. (CA) | 2003-05-08 | — | — | US | claimed |
| WO-2002100421-A1 | LOW MOLECULAR WEIGHT COMPONENTS OF CARTILAGE, COMPLEXES OF COPPER WITH AMINO ACIDS OR DI-PEPTIDES; PROCESSES FOR PREPARATION AND THERAPEUTIC USES THEREOF | LES LABORATOIRES AETERNA INC. (CA) | 2002-12-19 | — | — | WO | claimed |
| WO-1998009989-A1 | THE USE OF MURAMYLPEPTIDES IN THE TREATMENT OF MYELOSUPPRESSED OR OTHERWISE IMMUNOCOMPROMISED STATES | PEPTECH (UK) LIMITED (GB) | 1998-03-12 | — | — | WO | claimed |
| EP-0722332-A1 | COMPOUNDS FOR MEDICINAL USE | PEPTECH (UK) LIMITED (GB) | 1996-07-24 | — | — | EP | claimed |
| WO-1995010293-A1 | COMPOUNDS FOR MEDICINAL USE | PEPTECH (UK) LIMITED (GB) | 1995-04-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355813-A1 | Theranostic Silicon-Fluoride Heteroaromatic Systems and Methods Thereof | FRS2, PAICS, FGF23 | ERAP2 2337/4885ACE 2332/4885ECE1 1697/4885 |
| US-20030087830-A1 | Low molecular weight components of cartilage, complexes of metals with amino acids, DI-peptides and analogs thereof; processes for preparation and therapeutic uses thereof | TIE1, TEK, VEGFA | ERAP2 549/4885ACE 1848/4885ECE1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.